- $924.37m
- $891.53m
- $321.48m
- 81
- 38
- 84
- 76
Annual cashflow statement for MiMedx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.6 | -49.3 | -10.3 | -30.2 | 67.4 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | -1.36 | 27.9 | 17.2 | 17.3 | 12.1 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -20.1 | -15.7 | -14.1 | -9.03 | -18.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -39.4 | -30.3 | -1.98 | -17.9 | 26.8 |
| Capital Expenditures | -2.22 | -4.55 | -3.47 | -2.68 | -2.15 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 2.72 | 0 | 0.075 | 0.024 | 0 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 0.504 | -4.55 | -3.4 | -2.66 | -2.15 |
| Financing Cash Flow Items | -8.12 | -14.5 | -4.75 | -1.19 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 62.9 | 61.6 | -3.35 | -0.58 | -8.57 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 24 | 26.7 | -8.73 | -21.1 | 16.1 |